secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cosmos Health Inc. (COSM)
CIK:        0001474167
Form:       8-K
Filed at:   2023-09-14T23:59:59+00:00
Accession:  0001477932-23-006898
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cosmos Health targets FY2026 revenue >$180M and EBITDA >$20M; recaps 2023 milestones
--------------------------------------------------------------------------------

- Inaugural 2026 guidance: gross annual revenue over $180M and EBITDA exceeding $20M.
- Completed three acquisitions in 2023: Cana Laboratories, I. Bikas GP assets, and ZipDoctor telehealth.
- Nutraceutical brands Sky Premium Life and Mediterranation expanding into new sales channels and geographies.
- Maintains robust balance sheet with negligible debt; CEO's personal investment now exceeds $15M.
- Second phase of obesity product CCX0722 completed; clinical trials scheduled to start in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1474167/000147793223006898/0001477932-23-006898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1474167/000147793223006898/cosm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-23-006898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer